|
End-of-day quote
Taipei Exchange
2026-08-24
|
5-day change | 1st Jan Change | ||
| 22.60 TWD | 0.00% |
|
+0.67% | -12.23% |
| 08-13 | GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-02 | GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
New Antibody Drug Department | 5.48M | 30.08M | 2.54M | 14.7M | 37.86M | |||||
Total Assets | 1.37B | 1.7B | 1.53B | 1.3B | 1.53B | |||||
Income Tax Expense | - | - | 14.64M | - | 1.06M | |||||
D&A | 40.13M | 39.96M | 31.18M | 34.37M | 35.42M | |||||
Operating Income | -195M | -239M | -260M | -246M | -250M | |||||
Investment Funds | ||||||||||
Income Tax Expense | - | - | - | 24K | 35K | |||||
Operating Income | -64K | -64K | -64K | -64K | -64K | |||||
Total Assets | 20.47M | 20.58M | 20.59M | 20.76M | 20.7M | |||||
Operating Income | 60K | 60K | 60K | 60K | 60K | |||||
Total Assets | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Japan | 3.12M | 19.28M | 1.61M | 7.18M | 37.82M | |||||
Taiwan | 2.35M | 468K | 933K | 7.52M | 42K | |||||
Total Assets | 1.02B | 990M | 821M | 823M | 796M | |||||
India | - | 10.34M | - | - | - | |||||
United States | - | - | - | - | - | |||||
Other | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Stocks
- 4168 Stock
- Financials GlycoNex Incorporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
